Pfizer Vaccine’s Protection Against COVID , Is Short-Lived in Children Ages 5–11, Study Says.<br />A new study, published in medRxiv, .<br />found that the lower dose of Pfizer's coronavirus vaccine seems to be less effective than the higher-dose regimens that older children and adults receive. .<br />Data from over 1.2 million fully-vaccinated kids and adolescents was collected between Dec. 13 and Jan. 30.<br />Children ages 5 to 11 receive a 10 milligram dose <br />of the vaccine, which is one-third of the <br />amount given to other age brackets.<br />Children ages 5 to 11 receive a 10 milligram dose <br />of the vaccine, which is one-third of the <br />amount given to other age brackets.<br />Researchers at the NY State Department of Health found protection provided by that small of a dosage to drop from 68% to 12%.<br />Researchers at the NY State Department of Health found protection provided by that small of a dosage to drop from 68% to 12%.<br />Doses given to older children and adults only see effectiveness drop from 66% to 51%.<br />These results highlight the potential need to study alternative vaccine dosing for children and the continued importance [of] layered protections, including mask wearing, to prevent infection and transmission, Study authors, via NPR.<br />The study's results follow the delay in <br />emergency use authorization for Pfizer's <br />coronavirus vaccine for kids ages 6 months to 4 years old <br />due to new data suggesting the need for additional doses.<br />The study's results follow the delay in <br />emergency use authorization for Pfizer's <br />coronavirus vaccine for kids ages 6 months to 4 years old <br />due to new data suggesting the need for additional doses
